DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Brian Snyder - 1 Ali Mokdad - 1 Mokdad - 1 Irfan Khan - 1 Jennifer Kates - 1 Brad Pollock - 1 Nicole Iovine - 1 epidemiologist - 1
Top related locs:
Somerville , Massachusetts U.S Novavax Covid Eagle Rock , California
Top related orgs:
Walgreens - 1 Pfizer - 1 Moderna - 1 Centers for Disease Control - 1 CDC - 1 University of Washington - 1 CVS Pharmacy - 1 Los Angeles Times - 1

Search resuls for: "Arpa Garay"


3 mentions found


☆ Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
  + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +10 min
In this article PFEMRNANVAX Follow your favorite stocks CREATE FREE ACCOUNTA sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | ReutersThree years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine. Experts and vaccine makers can agree that low Covid vaccination rates are concerning, even as cases of the virus dwindle from their pandemic highs. However, Iovine of the University of Florida doesn't believe combination shots will have a significant effect on Covid vaccination rates. If combination shots don't do the trick, it's unclear what else could boost Covid vaccination rates down the line.
Persons: Brian Snyder, Ali Mokdad, Mokdad, Irfan Khan, Jennifer Kates, Brad Pollock, Nicole Iovine, epidemiologist, Iovine, Michael Yee, Albert Bourla, Arpa Garay, Garay, John Trizzino, Trizzino, Jamey Mock, Andrew Pekosz, Jefferies, Yee, doesn't Organizations: Walgreens, Reuters, Pfizer, Moderna, Centers for Disease Control, CDC, University of Washington, CVS Pharmacy, Los Angeles Times, KFF, UC Davis Health's, University of Florida, Jefferies, Arpa, CNBC, Istock, Getty, Johns Hopkins Bloomberg School of Public Health Locations: Somerville , Massachusetts, U.S, Novavax, Covid, Eagle Rock , California
☆ Moderna beats COVID vaccine sales expectations as deferred revenue rolls in
  + stars: | 2023-05-04 | by ( Patrick Wingrove Leroy Leo | Patrick Wingrove | Leroy Leo | ) www.reuters.com   time to read: +3 min
May 4 (Reuters) - Moderna Inc (MRNA.O) on Thursday reported stronger-than-expected sales of $1.9 billion for its COVID-19 vaccine in the first quarter, driven by a surge of revenue deferred from 2022, but left its 2023 sales expectations unchanged. Moderna said it continued to expect COVID vaccine sales of $5 billion for the year based on advance purchase agreements. Moderna expects an additional $3 billion in deferred vaccine revenue in the second half of 2023. The results came two days after the company's rival Pfizer reported better-than-expected COVID vaccine sales for the first quarter and maintained its expectations for full-year sales. Moderna had generated around $36 billion in sales over the last two years from its COVID vaccine, its only commercial product and one of the most widely used shots for the virus.
☆ Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand
  + stars: | 2023-02-23 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +3 min
Moderna on Thursday missed earnings expectation for the fourth quarter, as costs rose from surplus production capacity and lower demand for its Covid-19 vaccine, the company's only product on the market. Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share. Moderna has signed contracts for $5 billion in Covid vaccine deliveries for 2023. Moderna estimates U.S. market volume in fall 2023 will be 100 million doses, said Arpa Garay, the company's chief commercial officer. Garay said Moderna will leverage the infrastructure it already has in place for Covid to launch the RSV vaccine.
0 next >>
Total: 3